Host Cell Targets for Unconventional Antivirals against RNA Viruses

ABSTRACT: The recent COVID-19 crisis has highlighted the importance of RNA-based viruses. The most prominent members of this group are SARS-CoV-2 (coronavirus), HIV (human immunodeficiency virus), EBOV (Ebola virus), DENV (dengue virus), HCV (hepatitis C virus), ZIKV (Zika virus), CHIKV (chikungunya virus), and influenza A virus. With the exception of retroviruses which produce reverse transcriptase, the majority of RNA viruses encode RNA-dependent RNA polymerases which do not include molecular proofreading tools, underlying the high mutation capacity of these viruses as they multiply in the host cells. Together with their ability to manipulate the immune system of the host in different ways, their high mutation frequency poses a challenge to develop effective and durable vaccination and/or treatments. Consequently, the use of antiviral targeting agents, while an important part of the therapeutic strategy against infection, may lead to the selection of drug-resistant variants. The crucial role of the host cell replicative and processing machinery is essential for the replicative cycle of the viruses and has driven attention to the potential use of drugs directed to the host machinery as therapeutic alternatives to treat viral infections. In this review, we discuss small molecules with antiviral effects that target cellular factors in different steps of the infectious cycle of many RNA viruses. We emphasize the repurposing of FDA-approved drugs with broad-spectrum antiviral activity. Finally, we postulate that the ferruginol analog (18-(phthalimide-2-yl) ferruginol) is a potential host-targeted antiviral.

• Autores: Roa Linares, Vicky Constanza; Escudero Flórez, Manuela; Gallego Gómez, Juan Carlos; Vicente Manzanares, Miguel
• Tipo de recurso: Review article
• Fecha de publicación: 2023
• Institución: Universidad de Antioquia
• Repositorio: Repositorio UdeA
• Idioma: eng
• OAI Identifier: oai:bibliotecadigital.udea.edu.co:10495/45411
• Acceso en línea: https://hdl.handle.net/10495/45411
• Palabra clave: Antivirales; Antiviral Agents; COVID-19; ARN; RNA; Virus ARN; RNA Viruses; SARS-CoV-2; Replicación Viral; Virus Replication; Infección por el Virus Zika; Zika Virus Infection; Virus Zika; Zika Virus; https://id.nlm.nih.gov/mesh/D000071244; https://id.nlm.nih.gov/mesh/D000998; https://id.nlm.nih.gov/mesh/D000086382; https://id.nlm.nih.gov/mesh/D012313; https://id.nlm.nih.gov/mesh/D012328; https://id.nlm.nih.gov/mesh/D000086402; https://id.nlm.nih.gov/mesh/D014779; https://id.nlm.nih.gov/mesh/D000071243
• Rights: openAccess
• License: https://creativecommons.org/licenses/by/4.0/